NR3C2 and chronic kidney disease: In addition, a new generation of nonsteroidal selective mineralocorticoid receptor (MR) antagonists has also appeared in indications for DKD, of which finerenone significantly reduced proteinuria in a short‐term trial of both chronic kidney disease (CKD) and T2DM patients.10